Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 as Neoadjuvant Therapy for Resectable Melanoma
NCT01216787Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RO4929097 in melanoma, sponsored by National Cancer Institute. Planned start Sep 2010; status: withdrawn.
02
Drugs
RO4929097
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01216787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216787.